Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 24 , ISSUE 7 ( July, 2020 ) > List of Articles


Extrapulmonary Features of COVID-19: A Concise Review

Sachin A Adukia, Radhika S Ruhatiya, Ramya B Manjunath, Gagan N Jain

Citation Information : Adukia SA, Ruhatiya RS, Manjunath RB, Jain GN. Extrapulmonary Features of COVID-19: A Concise Review. Indian J Crit Care Med 2020; 24 (7):575-580.

DOI: 10.5005/jp-journals-10071-23476

License: CC BY-NC 4.0

Published Online: 22-11-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Typical manifestations of coronavirus disease (COVID-19) involve the upper and lower respiratory tract. But as the pandemic surges, we are encountering numerous case reports and series of extrapulmonary presentations of COVID-19 in the outpatient department. Abundant retrospective data have also cited various extrapulmonary complications in the hospitalized COVID-19 patients. This knowledge needs to be condensed and disseminated in order to improve COVID-19 surveillance and to reduce the accidental exposure of healthcare workers. Our review suggests that gastrointestinal tract, cardiovascular system, nervous system, renal system, and manifestations due to hematological abnormalities are common masqueraders to watch out for.

  1. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–637. DOI: 10.1002/path.1570. PMID: 15141377; PMCID: PMC7167720.
  2. Kim J, Thomsen T, Sell N, Goldsmith AJ. Abdominal and testicular pain: an atypical presentation of COVID-19. Am J Emerg Med 2020;38(7):1542.e1–1542.e3. DOI: 10.1016/j.ajem.2020.03.052.
  3. World Health Organization, Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). 2020.
  4. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020(5):1–7. DOI: 10.1038/s41591-020-0868-6.
  5. He D, Zhao S, Lin Q, Zhuang Z, Cao P, Wang MH, et al. The relative transmissibility of asymptomatic cases among close contacts. Int J Infect Dis 2020. DOI: 10.1016/j.ijid.2020.04.034.
  6. Yin G, Jin H. Comparison of transmissibility of coronavirus between symptomatic and asymptomatic patients: Reanalysis of the Ningbo COVID-19 data. JMIR Public Health Surveill 2020;6(2):e19464. DOI: 10.2196/19464.
  7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–1069. DOI: 10.1001/jama.2020.1585.
  8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020. 368. DOI: 10.1136/bmj.m1091.
  9. Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J 2020;41(22):2130. DOI: 10.1093/eurheartj/ehaa253.
  10. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA cardiology 2020. DOI: 10.1001/jamacardio.2020.1096.
  11. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology 2020. DOI: 10.1001/jamacardio.2020.0950.
  12. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020. DOI: 10.1016/j.pcad.2020.03.001.
  13. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133(9):1025–1031. DOI: 10.1097/CM9.0000000000000744.
  14. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 2018;72(17):2071–2081. DOI: 10.1016/j.jacc.2018.08.1043.
  15. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–407. DOI: 10.1016/j.healun.2020.03.012.
  16. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
  17. Dong N, Cai J, Zhou Y, Liu J, Li F. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. JACC: Heart Failure 2020;8(6):515–517. DOI: 10.1016/j.jchf.2020.04.001.
  18. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020;75(18):2352–2371. DOI: 10.1016/j.jacc.2020.03.031.
  19. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap!. Circulation 2020(1). DOI: 10.1161/CIRCULATIONAHA.120.047293.
  20. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of COVID-19 in New York city. N Engl J Med 2020;382(24):2372–2374. DOI: 10.1056/NEJMc2010419.
  21. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009;39(7):618–625. DOI: 10.1111/j.1365-2362.2009.02153.x.
  22. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8.
  23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.
  24. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
  25. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology 2020;77(6):1–9. DOI: 10.1001/jamaneurol.2020.1127.
  26. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.
  27. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92(6):552–555. DOI: 10.1002/jmv.25728.
  28. Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH. First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv 2020;202003:00015.
  29. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020. 201187. DOI: 10.1148/radiol.2020201187.
  30. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology 2020;19(5):383–384. DOI: 10.1016/S1474-4422(20)30109-5.
  31. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020;7(1):11. DOI: 10.1186/s40779-020-00240-0.
  32. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet 2020;395(10229):1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.
  33. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. Chin J Bur 2020;36(6):E005. doi: 10.3760/cma.j.cn501120-20200224- 00088.
  34. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020;92(6): 568–576. DOI: 10.1002/jmv.25748.
  35. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al. Acute cerebrovascular disease following COVID-19: a single, retrospective, observational study. Lancet 2020. DOI: 10.2139/ssrn.3550025.
  36. Omar S, Clarke R, Abdullah H, Brady C, Corry J, Winter H, et al. Respiratory virus infection up-regulates TRPV1, TRPA1 and ASICS3 receptors on airway cells. PLoS ONE 2017;12(2):e0171681. DOI: 10.1371/journal.pone.0171681.
  37. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 2020. DOI: 10.1093/cid/ciaa330.
  38. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory Dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter european study. Eur Arch Otorhinolaryngol 2020(8):1–1. DOI: 10.1007/s00405-020-05965-1.
  39. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease Severity: Clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol 2020;115(6):916–923. DOI: 10.14309/ajg.0000000000000664.
  40. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020(5):115. DOI: 10.14309/ajg.0000000000000620.
  41. D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clin Gastroenterol Hepatol 2020;18(8):1663–1672. DOI:
  42. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 2020;5(5):428–430. DOI: 10.1016/S2468-1253(20)30057-1.
  43. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterol 2020;158(6):1831–1833. DOI: 10.1053/j.gastro.2020.02.055.
  44. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434–435. DOI: 10.1016/S2468-1253(20)30083-2.
  45. Aroniadis OC, DiMaio CJ, Dixon RE, Elmunzer BJ, Kolb JM, Mendelsohn R, et al. Current knowledge and research priorities in the digestive manifestations of COVID-19. Clin Gastroenterol Hepatol 2020;18(8):1682–1684. DOI: 10.1016/j.cgh.2020.04.039.
  46. Tian Y, Rong L, Nian W, He Y. Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51(9):843–851. DOI: 10.1111/apt.15731.
  47. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69(6):1002–1009. DOI: 10.1136/gutjnl-2020-320926.
  48. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. Gastroenterol 2020. S0016-5085(20)30490-X 10.1053/j.gastro.2020.04.017.
  49. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nat 2020;579(7798):265–269. DOI: 10.1038/s41586-020-2008-3.
  50. Fang D, Ma J, Guan J, Wang M, Song Y, Tian D. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. Chin J Dig 2020;40(2020-02-23).
  51. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475–481. DOI: 10.1016/S2213-2600(20)30079-5.
  52. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, Caution on Kidney Dysfunctions of 2019-nCoV Patients medRxiv; 2020 10.1101/2020.02.;18.
  53. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. MedRxiv 2020;97(5):829–838. DOI: 10.1016/j.kint.2020. 03.005.
  54. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in china: a nationwide analysis. Europ Respirat J 2020;55(5):2000547. DOI: 10.1183/13993003.00547-2020.
  55. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020(6):1–2. DOI: 10.1007/s11255-020-02451-9.
  56. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nat 2003;426(6965):450–454. DOI: 10.1038/nature0214.
  57. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;138(5):575–578. DOI: 10.1001/jamaophthalmol.2020.1291.
  58. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19): a case report. Can J Ophthalmol 2020. DOI: 10.1016/j.jcjo.2020.03.003.
  59. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020;28(3):391–395. DOI: 10.1080/09273948.2020.1738501.
  60. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18(7): 1559–1561. DOI: 10.1111/jth.14849.
  61. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. Preprints 2020. 2020040345. DOI: 10.20944/preprints202004.0345.v1.
  62. Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020;191:148–150. DOI: 10.1016/j.thromres.2020.04.041.
  63. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 2020. DOI: 10.1161/CIRCULATIONAHA.120.047430.
  64. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography. Thromb Res 2020. DOI: 10.1016/j.thromres.2020.04.011.
  65. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. Lille intensive care COVID-19 and Obesity study group. High prevalence of Obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 2020;28(7):1195–1199. DOI: 10.1002/oby.22831.
  66. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translat Res 2020;220:1–13. DOI: 10.1016/j.trsl.2020.04.007.
  67. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica Chimica Acta 2020;506:145–148. DOI: 10.1016/j.cca.2020.03.022.
  68. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002;31(4):256–263. DOI: 10.1053/sarh.2002.28303.
  69. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382(17):e38. DOI: 10.1056/NEJMc2007575.
  70. Hall RCW, Hall RCW, Chapman MJ. The 1995 Kikwit Ebola outbreak: lessons hospitals and physicians can apply to future viral epidemics. Gen Hosp Psychiatry 2008;30(5):446–452. DOI: 10.1016/j.genhosppsych.2008.05.003.
  71. Naushad VA, Bierens JJ, Nishan KP, Firjeeth CP, Mohammad OH, Maliyakkal AM, et al. A systematic review of the impact of disaster on the mental health of medical responders. Prehosp Disaster Med 2019;34(6):632–643. DOI: 10.1017/S1049023X19004874.
  72. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020(5). DOI: 10.1111/jdv.16387.
  73. Sachdeva M, Gianotti R, Shah M, Lucia B, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci 2020;98(2):75–81. DOI: 10.1016/j.jdermsci.2020.04.011.
  74. Gianotti R. COVID 19 and the skin—heuristic review. Dermo Sprint 2020. In press.
  75. Joob B, Wiwanitkit V. Arthralgia as an initial presentation of COVID-19: observation. Rheumatol Int 2020(5):1. DOI: 10.1007/s00296-020-04561-0.
  76. Singhania N, Bansal S, Singhania G. An atypical presentation of novel coronavirus disease 2019 (COVID-19). Am J Med 2020;133(7):e365–e366. DOI: 10.1016/j.amjmed.2020.03.026.
  77. Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med 2020;38(7):1544.e1–1544.e3. DOI: 10.1016/j.ajem.2020.04.011.
  78. Wander P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis. Am J Gastroenterol 2020;115(6):941–942. DOI: 10.14309/ajg.0000000000000660.
  79. Weber S, Mayerle J, Irlbeck M, Gerbes AL. Severe liver failure during SARS-CoV-2 infection. Gut 2020;69(7):1365–1367. DOI: 10.1136/gutjnl-2020-321350.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.